EVO

Business Context and Reporting Period

Company: Evotec SE (Evotec AG)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2010 (First Half 2010)
Business Overview: Evotec is a drug discovery company operating through strategic alliances with pharmaceutical and biotech partners. The period marked a significant turnaround, with the company reporting its first profitable half-year in history, driven by milestone income and cost reductions.

Key Financial Metrics

Note: Liquidity includes cash, cash equivalents, and investments. The €67.9m figure represents an increase from the end of Q1 2010.

Material Changes vs. Prior Period

• Profitability Turnaround: The company moved from a €29.1 million operating loss in H1 2009 to a €0.3 million operating profit in H1 2010. This was primarily driven by high-margin milestone income and a drastic reduction in operating expenses.
• Expense Reduction: R&D expenses plummeted by 82% due to the closure of the US site, a focus on fewer core programs, and the transfer of EVT 100 development costs to partner Roche. SG&A costs decreased by 15% following restructuring.
• Revenue Composition: Revenue growth was fueled by milestone payments, specifically €2.0 million from Boehringer Ingelheim for Phase I initiation in neuropathic pain and €2.5 million for oncology program progression. Geographically, European revenue contribution increased to 50% (from 45% in H1 2009).
• Asset Realization: The company exercised put options on auction rate securities, selling them for €11.4 million, which improved cash availability.

Guidance, Outlook, and Risks

Guidance and Outlook

• Revenue Guidance Raised: Full-year 2010 revenue guidance increased to €52–54 million (previously €48–50 million), anticipating >20% growth.
• Liquidity Target: Year-end 2010 liquidity target confirmed at >€64 million, despite a planned €2 million cash outflow for the DeveloGen acquisition.
• Profitability Path: Management believes the company is on course to achieve sustainable profitability by 2012 at the latest.
• Order Book: Strong order book of €40 million as of June 30, 2010 (+21% vs. 2009), indicating growth into 2011.

Management Commentary and Unusual Items

• Acquisition (Post-Period): On July 14, 2010, Evotec signed an agreement to acquire DeveloGen AG for up to €14 million in shares plus earn-out. This adds metabolic disease expertise and two new alliances (Boehringer Ingelheim and Andromeda/Teva).
• Management Changes: Colin Bond appointed new CFO (Aug 12); Cord Dohrmann appointed new CSO (Sep 1). Former CFO Klaus Maleck moved to Corporate Development.
• Clinical Progress: Phase II study for EVT 101 (treatment-resistant depression) began patient recruitment in June. H3 receptor antagonist program nominated a development candidate (EVT 501).

Risks and Contingencies

• Clinical Failure: Risk that product candidates may fail in clinical trials or not achieve regulatory approval.
• Collaboration Risks: Uncertainty regarding the timing and success of benefits from partnerships and acquisitions.
• Revenue Volatility: Gross margins may remain volatile depending on the timing of milestone or out-licensing payments.

Investor Verification Checklist

• Milestone Sustainability: Verify the recurring nature of milestone income versus one-time events, as margins are heavily dependent on these payments.
• DeveloGen Integration: Assess the financial impact and strategic fit of the DeveloGen acquisition, including the €2 million cash outflow and share issuance.
• Roche Partnership: Monitor the progress of the EVT 101 Phase II trial, as a successful buy-back option could yield a $65 million lump sum.
• Cost Structure: Confirm that the 82% reduction in R&D expenses is sustainable and does not compromise future pipeline development.
• Liquidity Runway: Validate the ability to maintain >€64 million liquidity through year-end given the acquisition costs and operating cash flow needs.